Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Coeptis Therapeutics Holdings Inc COEP

Healthcare Biotechnology
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics... see more

Recent & Breaking News (NDAQ:COEP)

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

PR Newswire May 17, 2023

Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

PR Newswire May 10, 2023

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

PR Newswire April 18, 2023

Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies

PR Newswire March 29, 2023

Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine

PR Newswire March 21, 2023

Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling

PR Newswire February 7, 2023

Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program

PR Newswire January 31, 2023

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

PR Newswire November 22, 2022

Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell

PR Newswire November 15, 2022

Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast

PR Newswire November 8, 2022

Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments

PR Newswire November 2, 2022

Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.

PR Newswire October 31, 2022

Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology

PR Newswire September 21, 2022

LEGENDARY GLOBAL FOOTBALL STAR RONALDINHO JOINS EXPANSION TEAM OWNERSHIP GROUP IN MAJOR ARENA SOCCER LEAGUE

PR Newswire May 6, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ACC, CMPI, BHSE

PR Newswire April 19, 2022

Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement

PR Newswire April 19, 2022

Bull Horn Holdings Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Business Wire September 3, 2021

Bull Horn Holdings Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Business Wire May 28, 2021